Stock Market News
Oxford Biomedica 'fully valued' as Jefferies ups target price
Oxford Biomedica's long-awaited OXB-102 deal did not disappoint Jefferies, but analysts felt the share price was up with events.
The broker hiked its target price on the biopharmaceutical company from 825p to 1,100p, but noted that with an "insufficient near-term upside" left, it was time to lower the stock to 'hold' from its former 'buy' rating.
Despite the downgrade, Jefferies said it remained confident that Oxford Biomedica's Parkinson's treatment was on a path to sustainable profitability and envisages an "escalating interest" in its proprietary Lenti platform, the long-awaited Phase I/II trial set to start by the end of the year.
Jefferies felt Oxford Biomedica's Axovant deal, which saw OXB-102 licensed to Axovant for $30m upfront, up to $812.5m in future milestones and 7%-10% royalties on sales, was "critical" to the firm as the terms "amply surpass" its prior $200m and 8%-11% assumptions.
Jefferies said, "The recent deal with Axovant for AXO-Lenti-PD increases confidence OXB can successfully establish externally funded vehicles or secure out-licensing deals for the continued clinical development of its two remaining priority pipeline programmes, which we believe should raise awareness of these largely overlooked assets."
"However, after the recent share price rally, we believe the stock is fully valued, hence our downgrade to 'hold'", the broker added.
The broker also noted that, importantly, its model suggested that Oxford Bio now had sufficient cash to fund expansion, repay its debt facility by 2020, and deliver sustainable profitability moving forward.
The broker hiked its target price on the biopharmaceutical company from 825p to 1,100p, but noted that with an "insufficient near-term upside" left, it was time to lower the stock to 'hold' from its former 'buy' rating.
Despite the downgrade, Jefferies said it remained confident that Oxford Biomedica's Parkinson's treatment was on a path to sustainable profitability and envisages an "escalating interest" in its proprietary Lenti platform, the long-awaited Phase I/II trial set to start by the end of the year.
Jefferies felt Oxford Biomedica's Axovant deal, which saw OXB-102 licensed to Axovant for $30m upfront, up to $812.5m in future milestones and 7%-10% royalties on sales, was "critical" to the firm as the terms "amply surpass" its prior $200m and 8%-11% assumptions.
Jefferies said, "The recent deal with Axovant for AXO-Lenti-PD increases confidence OXB can successfully establish externally funded vehicles or secure out-licensing deals for the continued clinical development of its two remaining priority pipeline programmes, which we believe should raise awareness of these largely overlooked assets."
"However, after the recent share price rally, we believe the stock is fully valued, hence our downgrade to 'hold'", the broker added.
The broker also noted that, importantly, its model suggested that Oxford Bio now had sufficient cash to fund expansion, repay its debt facility by 2020, and deliver sustainable profitability moving forward.
Related share prices |
---|
Oxford Biomedica (OXB) share price |
Stock News headlines are gathered from financial news sources around the web. Views and opinions on each item are from their respective authors and website. They are not opinions of LiveCharts.co.uk
Get a free widget for your website with our latest headlines.
You can now add our live prices and new headlines to your website.The news widget features quotes for Oil prices, spot Gold price and Indices plus a choice of news channel for healines.
Top Shares pages
- Share price quotes
- Share charts
- Share watch list
- Company Results Calendar
- Top Large UK Shares
- UK Market Sectors
- Stock market news
- Company news
- Share tips
- A-Z company search
More share features
POPULAR Share Prices
- Royal Mail share price
- Lloyds share price
- HSBC share price
- Barclays share price
- Prudential share price
- Santander share price
- NEXT share price
- Diageo share price
- BP share price
- Vodafone share price
- British Airways
- Centrica share price
- Tesco share price
- Taylor Wimpey Share Price
- National Grid
- GKP Share Price
- Marks and Spencer
- Rolls Royce
- Rio Tinto
- THG Share Price
- Aviva Share Price
- Boil Share price
- Easyjet Share Price
- Genedrive Share Price
- SSE Share Price
- IAG Share Price
- Boohoo share price
- HE1 share price
- AVCT share price
- BOOM share price